Updates in the Management of Precursor Conditions (SMM and MGUS) | 2026 Multiple Myeloma Symposium
🛍️ Products Mentioned (1)
Betsy O’Donnell, MD, shares an update on two precursor conditions of multiple myeloma – smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) – including risk of progression, how they’re currently being treated, and ongoing studies to prevent progression. Learn more about our Center for Early Detection and Interception of Blood Cancers: https://www.dana-farber.org/cancer-care/treatment/early-detection-interception/blood-cancers
🎬 More from Dana-Farber Cancer Institute
Understanding Chemo Neuropathy: A Webinar by the Older Adults with GI Cancer Program | Dana-Farber
19 views
Learning About Chronic Lymphocytic Leukemia | Lymph Notes: A Lymphoma Learning Series
112 views
ASCO26: David Reardon, MD Glioblastoma Vaccine | Dana-Farber Cancer Institute
106 views
Society of Gynaecological Oncology Congress 2026: Tara Berman, MD | Dana-Farber Cancer Institute
30 views
ASCO26: Julia Rotow, MD Silevertinib in Lung Cancer | Dana-Farber Cancer Institute
55 views
ASCO26: Atish Choudhury, MD, PhD A-DREAM/Alliance A032101 | Dana-Farber Cancer Institute
38 views